Document Detail

The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
MedLine Citation:
PMID:  17987788     Owner:  NLM     Status:  MEDLINE    
Current management of bone metastases involves a multimodal approach. Aminobisphosphonates (BPs) are a valid weapon in the treatment of skeletal localization of tumour disease. Patients with bone metastases from breast and lung cancer were enrolled in order to evaluate the impact of the addition of bisphosphonates therapy to standard treatments in terms of (i) pain control, (ii) quality of life (QoL) and (iii) toxicity and to evaluate (iv) any relations between clinical activity and the occurrence of SREs. A total of 60 patients were included in the study. Median age was 76 years (range 40-83). The majority of patients were treated with chemotherapy or hormonal therapy. All patients received zoledronic acid (ZOL) (4 mg) every 3-4 weeks for at least 3 cycles. No significant improvement in Performance Status of patients after 12 cycles of ZOL (p = 0.1672) was recorded. A statistically significant early and long-lasting amelioration of both pain, narcotic scores and QoL was found. Twenty-one patients (48%) experienced at least one SRE during the study. The most common SRE was radiation to bone (30% of patients). An inverse correlation between bone tumour response and SREs was also found (p = 0.019). ZOL addition induces a clinical benefit and improves QoL of patients with bone metastases. Moreover, the occurrence of bone clinical response is related to a reduced risk of SREs.
G Facchini; M Caraglia; D Santini; G Nasti; A Ottaiano; S Striano; P Maiolino; M Ruberto; F Fiore; G Tonini; A Budillon; R V Iaffaioli; G L Zeppetella
Related Documents :
15199528 - Gemcitabine plus docetaxel administered every other week as first-line treatment of met...
17717668 - Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: lo...
18226208 - Nail changes secondary to docetaxel chemotherapy : a case report.
19139178 - Weekly docetaxel, cisplatin, and irinotecan (tpc): results of a multicenter phase ii tr...
3473428 - History of patients with chronic granulocytic leukaemia observed in 1974-1984.
6279348 - The natural history of metastatic synovial sarcoma: experience of the southwest oncolog...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of experimental & clinical cancer research : CR     Volume:  26     ISSN:  0392-9078     ISO Abbreviation:  J. Exp. Clin. Cancer Res.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-11-08     Completed Date:  2007-12-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308647     Medline TA:  J Exp Clin Cancer Res     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  307-12     Citation Subset:  IM    
Medical Oncology Division B, National Cancer Institute, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bone Density Conservation Agents / administration & dosage,  adverse effects,  therapeutic use*
Bone Neoplasms / secondary*
Breast Neoplasms / drug therapy*,  pathology*
Diphosphonates / administration & dosage,  adverse effects,  therapeutic use*
Imidazoles / administration & dosage,  adverse effects,  therapeutic use*
Lung Neoplasms / drug therapy*,  pathology*
Middle Aged
Musculoskeletal System / drug effects
Quality of Life
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients usin...
Next Document:  Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in...